Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review

Gunar Stemer 1,2* and Rosa Lemmens-Gruber1

Abstract

Background: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) represent worldwide health problems with an epidemic extent. Therefore, attention must be given to the optimisation of patient care, as gaps in the care of CKD and ESRD patients are well documented. As part of a multidisciplinary patient care strategy, clinical pharmacy services have led to improvements in patient care. The purpose of this study was to summarise the available evidence regarding the role and impact of clinical pharmacy services for these patient populations.

Methods: A literature search was conducted using the Medline, Embase and International Pharmaceutical Abstracts databases to identify relevant studies on the impact of clinical pharmacists on CKD and ESRD patients, regarding disease-oriented and patient-oriented outcomes, and clinical pharmacist interventions on drug-related problems.

Results: Among a total of 21 studies, only four (19%) were controlled trials. The majority of studies were descriptive (67%) and before-after studies (14%). Interventions comprised general clinical pharmacy services with a focus on detecting, resolving and preventing drug-related problems, clinical pharmacy services with a focus on disease management, or clinical pharmacy services with a focus on patient education in order to increase medication knowledge. Anaemia was the most common comorbidity managed by clinical pharmacists, and their involvement led to significant improvement in investigated disease-oriented outcomes, for example, haemoglobin levels. Only four of the studies (including three controlled trials) presented data on patient-oriented outcomes, for example, quality of life and length of hospitalisation. Studies investigating the number and type of clinical pharmacist interventions and physician acceptance rates reported a mean acceptance rate of 79%. The most common reported drug-related problems were incorrect dosing, the need for additional pharmacotherapy, and medical record discrepancies.

Conclusions: Few high-quality trials addressing the benefit and impact of clinical pharmacy services in CKD and ESRD patients have been published. However, all available studies reported some positive impact resulting from clinical pharmacist involvement, including various investigated outcome measures that could be improved. Additional randomised controlled trials investigating patient-oriented outcomes are needed to further determine the role of clinical pharmacists and the benefits of clinical pharmacy services to CKD and ESRD patients.

Background

Chronic kidney disease (CKD) represents a major public health problem in developed and developing countries. It is estimated that approximately 5% of the adult U.S. population is affected by CKD, which is defined as serum creatinine concentrations greater than 1.2 to 1.5 mg/dL [1]. The European Kidney Health Alliance (EKHA) reports that approximately 10% of European citizens are affected by some degree of CKD [2].

CKD and end-stage renal disease (ESRD) are associated with an increased risk of mortality, increased rate of hospitalisation, and decreased life expectancy [3]. Progression from early to late stages of CKD generally results in the onset of new symptoms and concomitant complications. Frequent complications and comorbidities of CKD include fluid and electrolyte abnormalities,
anaemia, secondary hyperparathyroidism and renal osteodystrophy, hypertension and hyperlipidaemia, metabolic acidosis, and several other comorbidities involving malnutrition, pruritus and uremic bleeding. CKD patients are at increased risk of cardiovascular disease (CVD), which includes coronary heart disease (CHD), cerebrovascular disease, peripheral vascular disease, and heart failure. The management of underlying and evident comorbidities (either as causes or consequences of CKD) and the prevention or delay of its progression to ESRD are complex.

In ESRD patients, the initiation of renal replacement therapies (RRTs), such as long-term dialysis (including haemodialysis (HD) or peritoneal dialysis (PD)) or transplantation, is usually indicated to relieve uremic symptoms and detoxify, whereas kidney transplantation (cadaveric or living donor transplantation) is the therapy of choice for ESRD [4].

Multidisciplinary health care teams of physicians, nurses, dieticians, and clinical pharmacists share the goal of preventing disease progression and managing comorbid conditions in CKD and ESRD patients. As specialists in pharmacotherapy, clinical pharmacists are routinely involved in patient care and interact with other health care professionals, addressing multiple, often unmet needs for pharmacotherapy optimisation. Ideally, this happens through a preventive, rather than a reactive, approach. Evidence from the literature supports the involvement of clinical pharmacists in several disease areas and underlines the positive patient outcomes and improvement of care that result [5,6].

The medical management of predialysis and dialysis patients involves complex and highly variable pharmacotherapy, including frequent monitoring and evaluation to ensure optimal pharmacotherapy, adherence to medication, and control of comorbidities and other risk factors. A high number of prescribed medications, poor medication adherence, and frequent dosage changes may contribute to drug-related morbidity and related problems [7]. Several studies report poor quality and gaps in the care of CKD patients with respect to the treatment of comorbidities, referrals to specialists, and the preparation for RRTs [8,9].

Clinical pharmacists are directly engaged in the care of CKD and ESRD patients in different settings. Various possibilities and opportunities for clinical pharmacists to contribute to this field are described and exemplarily supported by evidence in an American College of Clinical Pharmacy (ACCP) opinion paper [10].

This literature review aims to systematically summarise the published evidence on the role of clinical pharmacists in the care of CKD and ESRD patients across different settings, to synthesise and highlight findings on the impact of clinical pharmacists, their various key activities, and their main areas of involvement, and to describe the different characteristics of clinical pharmacy services for the CKD and ESRD patient population.

Methods
A literature search was conducted using the Medline (1970 - Week 46, 2010), EMBASE (1996 - Week 45, 2010) and International Pharmaceutical Abstracts (IPA) (1970 - Oct 2010) databases to identify relevant articles. In Medline, the following combinations of Medline Medical Subject Headings (Mesh) terms were used as our search strategy: ("pharmacy service, hospital" OR "pharmacists" OR "pharmaceutical services") AND ("renal insufficiency" OR "kidney" OR "renal replacement therapy"). In Embase and IPA, the search strategy combined the terms ("clinical pharmacy" OR "pharmaceutical care" OR "pharmacist" OR "hospital pharmacy") AND ("renal insufficiency" OR "kidney" OR "renal replacement therapy"). The references sections of the returned publications and review articles were further screened for additional hits. Data were extracted and reviewed by the first study author (GS) and independently reviewed by the second author (RLG). Discrepancies were solved by discussion among the study authors.

All studies addressing the impact of clinical pharmacy services (either at the patient or the physician level) on the care of CKD and ESRD patients for both HD and PD were included. Therefore all studies reporting on disease-oriented and patient-oriented outcomes, and clinical pharmacist interventions on drug-related problems (DRPs) together with the physician acceptance rate, were assessed. Studies addressing the impact of clinical pharmacy services in kidney transplantation were excluded. A detailed review of these kinds of services was recently published [11]. Detailed inclusion and exclusion criteria are described in Table 1. The weakest study design included was observational and solely descriptive, as a high number of randomised controlled trials could not be anticipated. Results published in abstract form (e.g., congress abstracts) were included only if they provided numerically assessable data, such as outcome data, the number of resolved DRPs, or physician acceptance rates.

Predefined data parameters (namely, the study design, duration and setting, the number of included patients, the types of interventions, the relevant outcomes, the results, and available statistical values) were extracted from the literature, summarised in an Excel spreadsheet, and reviewed.

Results
The initial Medline, Embase and IPA searches yielded 339, 199, and 323 citations, respectively. The detailed search results are described in Figure 1.
A total of 861 citations were initially screened for inclusion criteria, and after removing duplicates, a total of 21 citations remained for full review and analysis. The predominant reason for exclusion was a lack of interventional and/or assessable data. Several initial citations had to be excluded because they provided data only on the impact of screening on appropriate renal dosing, with or without computerised support, or they provided only economic data.

**General study characteristics**

Detailed descriptions on the included studies of CKD and ESRD patients, including relevant interventions, outcomes, and results, are shown in Tables 2 and 3, respectively. Three study types were identified, including 14 descriptive studies (DSs) (66.7%), four (randomised) controlled (R)CTs (19%), and three before-after studies (BASs) (14.3%). A total of seven (33.3%) of the published studies were on only available as abstracts. The earliest included study was published in 1993. The study sites were predominantly located in the United States (n = 16, 76.2%). The majority of the studies investigated the impact of the clinical pharmacist on the HD patient population only (n = 15, 71.4%). Six studies (28.6%) addressed care issues in CKD patients. Only two studies (9.5%) [12,13] included PD patients. Most of the studies were performed in an ambulatory HD or CKD patient care setting (n = 17, 81%), whereas only four studies contained data on in-hospital clinical pharmacist activities (see Tables 2 and 3). Using data from 18 reported studies, the median (range) number of study participants was 60 (10-408), and the median (range) study duration was six (1-32) months.

**Scope of clinical pharmacy activities**

The interventions performed in the included studies could be roughly grouped into the following categories: (1) general clinical pharmacy services (n = 12, 57.1%) [12-23], (2) clinical pharmacy services focusing on disease management (n = 7, 33.3%) [24-30] and (3) clinical pharmacy services with a focus on educational activities (n = 2, 9.5%) [31,32]. A listing of reported clinical pharmacist activities is provided in Table 4. The included studies report on the clinical pharmacists’ involvement in the management of anaemia, lipid disorders, cardiovascular disease, hypertension, and diabetes in CKD or ESRD patients to various extents.

**Outcomes**

In 47.6% (n = 10) of the included studies [13,16,24-31], disease-oriented outcomes were reported, whereas patient-oriented outcome data were only available in four studies (19%) [22,23,31,32]. A synthesis of the disease- and patient-oriented outcome data is shown in Table 5. Four controlled trials (three of which were randomised) revealed that clinical pharmacy interventions had a positive impact on patient-oriented outcomes in the intervention group as compared to the available standard of care.

The third type of outcome parameter in the included studies was the total number of clinical pharmacist interventions performed or recommendations given together with the physician acceptance rate. These were considered primary (n = 7) or additional secondary (n = 3) outcome parameters in 10 out of 21 (47.6%) studies.

In the subanalysis of DSs, a weighted mean acceptance rate (± SD) based on study size of 78.7% (± 19.5) was calculated. DRPs were mainly classified according to the...
| First author, (Year), Population | Design | N (INT/CT)a | Duration (months) | Interventions | Relevant outcomesb | Results | p-Value |
|----------------------------------|--------|-------------|------------------|---------------|-------------------|---------|---------|
| Lim SB et al. [14], (2003), CKD inpts | DS     | 60          | 2                | MR, therapeutic monitoring, feedback to physicians | No./Types of DRPs | 86      |         |
|                                  |        |             |                  |               | Transcription errors | 44%     |         |
|                                  |        |             |                  |               | Renal dosage adjustments | 10%     |         |
|                                  |        |             |                  |               | PhAR               | 93%     |         |
|                                  |        |             |                  |               | Significance       |         |         |
|                                  |        |             |                  |               | Somewhat significant | 26%     |         |
|                                  |        |             |                  |               | Significant        | 67%     |         |
|                                  |        |             |                  |               | Very significant   | 4%      |         |
| Patel HR et al. [15], (2005), CKD outpts | DS     | 119         | NR               | Review of medical records, evaluations of DRPs, therapeutic recommendations | No. of DRPs | 381 (100%) |         |
|                                  |        |             |                  |               | Types of Interventions |         |         |
|                                  |        |             |                  |               | Change of drugs     | NR      |         |
|                                  |        |             |                  |               | Change of dosage    | NR      |         |
|                                  |        |             |                  |               | Interval adjustments | NR      |         |
|                                  |        |             |                  |               | PhAR               | 40.9%   |         |
| Allenet B et al. [31], (2007), CKD outpts | BAS    | 10          | 3                | Pharmacist-managed anaemia educational programmes | Knowledge (% of right answers on a 7-item questionnaire) at baseline vs. follow-up at Month 3 | 80 ± 18/93 ± 10 | NS     |
|                                  |        |             |                  |               | QOL judged on a LAS (0-10) at baseline vs. Month 3 |         |         |
|                                  |        |             |                  |               | Energy             | 3.3 ± 1.7/7.1 ± 1.7 | < 0.05 |
|                                  |        |             |                  |               | Daily activities   | 4.9 ± 2.1/7.7 ± 1.9 | < 0.05 |
|                                  |        |             |                  |               | General well-being | 4.6 ± 2.2/7.5 ± 1.6 | < 0.05 |
| Bucaloiu ID et al. [24], (2007), CKD outpts | DS     | NR          | 32               | Pharmacist-managed anaemia programmes compared to PCP-managed pts | Weekly erythropoietin dose | 6.698/12,000 units | 0.0001 |
|                                  |        |             |                  |               | Time to achieve Hb goal | 47.5/62.5 days | 0.11 |
|                                  |        |             |                  |               | Maintenance of Hb values in target range | 69.8/43.9% | 0.0001 |
|                                  |        |             |                  |               | Maintenance of Tsat values in target range | 64.8/40.4% | 0.043 |
| Joy MS et al. [25], (2007), CKD outpts | DS     | 128         | 28               | Clinical pharmacist-managed anaemia programmes with darbopoietin | % of pts achieving Hb target compared to retrospective baseline analysis of data (before clinical implementation) | 78/41% |         |
|                                  |        |             |                  |               | Disease control parameters: Change from baseline to last follow-up visit (INT/CT) |         |         |
|                                  |        |             |                  |               | Blood pressure      | -6/+6.8 mmHg |         |
|                                  |        |             |                  |               | HbA1c              | -0.2/0% |         |
|                                  |        |             |                  |               | Haemoglobin         | 1.05/-1.85 g/dL |         |
|                                  |        |             |                  |               | Medication adherence (pill count) | 97.2/88.2% |         |

BAS before-after study, CKD chronic kidney disease, CT controlled trial, DS descriptive study, DRP drug-related problem, Hb haemoglobin, HbA1c glycosylated haemoglobin, LAS linear analogue scale, MR medication review, No. number, NR not reported, NS not significant, PC pharmaceutical care, PCP primary care physician, PhAR physician acceptance rate, pts patients, QOL quality of life, SOC standard of care, Tsat transferrin saturation

a Number of included patients in the intervention (INT) or control (CT) group.

b For brevity, only the three most commonly performed interventions/drug-related problems are listed.
Table 3 Detailed description of the included publications on dialysis patients

| First author, Year, Population | Design | N (INT/CT) | Duration (months) | Interventions | Relevant outcomes b | Results | p-Value |
|-------------------------------|--------|------------|-------------------|---------------|-------------------|---------|---------|
| Tang I et al. [17], (1993), HD outpts | DS     | NR         | 6                 | Therapeutic interventions provided by CP | No/Types of interventions | 205 (100%) |         |
|                               |        |            |                   |               | Drug selection    | 66 (32.2%) |         |
|                               |        |            |                   |               | Drug discontinuation | 39 (19.0%) |         |
|                               |        |            |                   |               | Dose selection    | 50 (24.4%) |         |
|                               |        |            |                   |               | Significance of interventions | |         |
|                               |        |            |                   |               | Preservation of major organ function | 34.6% |         |
|                               |        |            |                   |               | Improvement in quality of care | 62.4% |         |
|                               |        |            |                   |               | PhAR              | 91.7% |         |
| Kaplan B et al. [18], (1994), HD outpts | DS     | 24         | NR                | Focused DT review programmes | No. of recommendations/informative comments | 114/85 |         |
|                               |        |            |                   |               | PhAR              | 76% (implemented 70%) |         |
| Grabe DW et al. [19], (1997), HD outpts | DS     | 45         | I                 | DT reviews by CP Therapeutic recommendations | No/Types of DRPs | 126 (100%) |         |
|                               |        |            |                   |               | Drug interactions | 35 (27.5%) |         |
|                               |        |            |                   |               | Dialysis-specific DRPs | 33 (26.5%) |         |
|                               |        |            |                   |               | PhAR              | 81% |         |
|                               |        |            |                   |               | No. of interventions | 102 |         |
|                               |        |            |                   |               | 1 - adverse significance | 0% |         |
|                               |        |            |                   |               | 2 - no significance | 6.9% |         |
|                               |        |            |                   |               | 3 - somewhat significant | 0% |         |
|                               |        |            |                   |               | 4 - significant | 78% |         |
|                               |        |            |                   |               | 5 - very significant | 4.9% |         |
|                               |        |            |                   |               | 6 - extremely significant | 1% |         |
| Possidente CJ et al. [12], (1999), HD and PD inpts | DS     | 37         | 3.5               | CPS (MR, pts interviews, identification and resolution of DRPs) | No/Types of DRPs | 161 |         |
|                               |        |            |                   |               | Pts did not receive drug | |         |
|                               |        |            |                   |               | Overdosage | |         |
|                               |        |            |                   |               | Labs needed | |         |
|                               |        |            |                   |               | More DRPs (77) at admission vs. discharge (41) | < 0.011 |         |
|                               |        |            |                   |               | PhAR              | 95.7% |         |
|                               |        |            |                   |               | Significance | |         |
|                               |        |            |                   |               | Somewhat significant | 24.7% |         |
|                               |        |            |                   |               | Significant | 58.4% |         |
|                               |        |            |                   |               | Very significant | 16.9% |         |
| Study | Participants | BAS | PTs | Intervention Description | Outcome Measures |
|-------|--------------|-----|-----|--------------------------|------------------|
| To LL et al. [26], 2001, HD outpts | BAS 49 6 |  | Pharmacist-managed programmes compared to physician-managed pts | Mean HCT (± SD) during physician period vs. pharmacist period: 35.36 ± 3.33/36.21 ± 3.46% 0.20 | Total EPO dose: 8.5/7.7 million units 0.37 Total elemental iron dose oral: 85.605/95.550 mg 0.64 Total elemental iron dose i.v.: 13,600/33,025 mg < 0.001 Mean (± SD) Tsat level: 29.82 ± 14.92/30.78 ± 13.17% 0.66 |
| Viola RA et al. [27], 2002, HD outpts | DS 26 6 |  | Pharmacist-managed hyperlipidaemia programmes with HD pts (laboratory management, counselling, statin initiation, and adjustments) | % of pts achieving LDL cholesterol target at baseline vs. Month 6: 58%/88% 0.015 Mean LDL (± SD) cholesterol at baseline vs. Month 6: 96c5/80 ± 3 mg/dL < 0.01 Mean total cholesterol (± SD) at baseline vs. Month 6: 170 ± 7/151 ± 4 mg/dL < 0.01 | No./Types of interventions: Dose increase 6 Drug change 5 Therapy initiation 2 |
| Kimura T et al. [28], 2004, HD outpts | DS 41 9 |  | Pharmacist-managed anaemia programmes | No. pts achieving the HCT target of >30% at baseline vs. Month 9: 7 (17.1%)/32 (78%) No. pts with EPO dose reductions due to intervention: 23 (56%) |
| Manley HJ et al. [29], 2004, HD outpts | DS 408 NR |  | Implementations of treatment algorithms for CV disease in HD pts by a pharmacist, collections of CV medication-related issues and recommendations to nephrologists, pts interview, MR | No. of recommendations: 1575 PhAR 79.8% Impact of recommendations on pts care: Improvement 89.9% No impact 7.6% Worsened pts care 2.4% LDL cholesterol -31.2 mg/dL < 0.001 HbA1C -0.3% NS Adjusted CV mortality hazard ratio: 0.48 (CI 0.18, 1.3) |
| Walton T et al. [30], 2005, HD outpts | DS 278 26 |  | Pharmacist-managed anaemia programmes | Hb value at baseline and Month 6: 9.5/11.8 g/dL Mean (± SD) ferritin at baseline and Month 6: 280.9 ± 326/431 ± 232.1 ng/mL |

**Note:** For Table 3, please refer to the full publication for the detailed description of the included publications on dialysis patients.
Table 3 Detailed description of the included publications on dialysis patients (Continued)

| Study | Design | N  | No./Types of interventions | Disease control parameters at baseline vs. follow-up visit at Day 90 |
|-------|--------|----|----------------------------|---------------------------------------------------------------|
| Sathvik BS et al. [32], (2007), HD outpts | RCT 90 4 | Pharmacist-provided pts education | Medication knowledge (MKAQ) at baseline, Month 2 and 4 in Group 1 and 2 |
|       |        |     |                           | Improvement in MKAQ scores in Group 1 compared to baseline and to Group 2 at Month 2 |
|       |        |     |                           | No significant improvement in MKAQ scores in Group 2 compared to baseline at Month 2 |
|       |        |     |                           | Improvement in MKAQ scores in Group 2 at Month 4 compared to baseline and to scores at Month 2 |
|       |        |     |                           | Decrease in MKAQ scores in Group I at Month 4 compared to Month 2 |
| Erickson Al et al. [20], (2008), HD in- and outpts | DS 1184 4 pts visits | Prospective order review by CP and general CPS | Compliance with prospective order review |
|       |        |     |                           | 1059 (89.4%) |
|       |        |     |                           | No./Types of interventions |
|       |        |     |                           | 77 (100%) |
|       |        |     |                           | Therapeutic-related |
|       |        |     |                           | 11 (14.3%) |
|       |        |     |                           | Safety-related |
|       |        |     |                           | 49 (63.6%) |
|       |        |     |                           | Compliance-related |
|       |        |     |                           | 17 (22.1%) |
|       |        |     |                           | PhAR |
|       |        |     |                           | 100% |
| Castro R et al. [13], (2009), HD in- and outpts | BAS 60 6 | MTM | Disease control parameters at baseline vs. follow-up visit at Day 90 |
|       |        |     | SBP (MTM) 150 ± 22/144 ± 18 mmHg 0.12 |
|       |        |     | SBP (non-MTM) 143 ± 21/145 ± 25 mmHg NS |
|       |        |     | HbA1c (MTM) 9.2 ± 1.6/9.0 ± 2.0% 0.58 |
|       |        |     | HbA1c (non-MTM) 6.2 ± 1.2/6.5 ± 1.4% NS |
|       |        |     | Phosphorus (MTM) 6.2/5.6 mg/dL .096 |
|       |        |     | Calcium/phosphorous product (MTM) 56 ± 19/50 ± 16 .03 |
| Mirkov S [21], (2009), HD outpts | DS 64 8 | DT reviews by CP | No./types of DRPs |
|       |        |     |                           | 278 (100%) |
|       |        |     |                           | Non-adherence |
|       |        |     |                           | 61 (22%) |
|       |        |     |                           | Overdose |
|       |        |     |                           | 26 (9.3%) |
|       |        |     |                           | Untreated indication |
|       |        |     |                           | 24 (8.6%) |
| Pai AB et al. [22], (2009), HD outpts | RCT 104 24 | INT: PC, DT reviews by CP | No./Types of DRPs |
|       |        |     |                           | 530 (100%) |
|       |        |     |                           | Drug record discrepancy |
|       |        |     |                           | 133 (25%) |
|       |        |     |                           | Untreated indication |
|       |        |     |                           | 111 (21%) |
system presented by Strand et al. [33]. However, in several included studies, information on classification methodology was scarce, or a system developed by the authors was used. The DRPs most frequently described in the included studies were untreated indications, super- or supratherapeutic dosages and consequent dose adjustments, and medication record discrepancies. Assessments of the clinical significance of clinical pharmacist interventions were performed and reported in five of 10 included studies. For this purpose, the significance criteria published by Hatoum et al. [34] was used in two studies [12,19]. Unspecified categorisation systems were used in the other studies. Bias minimisation methods used during clinical significance assessments generally included a review by independent clinical pharmacists or the achievement of consensus among the ratings of clinicians, nephrologists and pharmacists.

Information on the drug classes among which the clinical pharmacists detected the majority of DRPs was reported in five of 10 included studies. For this purpose, the significance criteria published by Hatoum et al. [34] was used in two studies [12,19]. Unspecified categorisation systems were used in the other studies. Bias minimisation methods used during clinical significance assessments generally included a review by independent clinical pharmacists or the achievement of consensus among the ratings of clinicians, nephrologists and pharmacists.

Table 3 Detailed description of the included publications on dialysis patients (Continued)

| Pai AB et al. (2009), HD outpts | RCT 107 (61/46) | INT: PC, DT reviews by CP | Total RQLP scores at Year 1 compared to baseline INT/CT | Worsening in Total RQLP score at Year 1 in CT group (88 ± 31/71 ± 34) | 0.03
| CT: SOC, DT reviews by dialysis nurse | Total RQLP scores at Year 2 compared to baseline INT/CT | Improvement in INT/CT group, no statistically significant difference |

BAS before-after study, CP clinical pharmacist, CPS clinical pharmacy services, CV cardiovascular diseases, DRP drug-related problem, DS descriptive study, DT drug therapy, EPO erythropoietin, HbA1c, glycosylated haemoglobin, HCT haematocrit, HD haemodialysis, Hb haemoglobin, LDL low-density lipoprotein, LOS length of stay, MKAQ medication knowledge assessment questionnaire, MR medication review, MTM medication therapy management service, No. number, NR not reported, NS not significant, PC pharmaceutical care, PhAR physician acceptance rate, pts patients, RCT randomised controlled trial, RQLP renal quality of life profile, SBP systolic blood pressure, SD standard deviation, SOC standard of care

* Number of included patients in the intervention (INT) or control (CT) group

For brevity, only the three most commonly performed interventions/drug-related problems are listed.

Discussion

Our systematic review synthesises evidence on the impact of clinical pharmacist involvement in DRPs in general, with respect to different comorbidities (e.g., anaemia and lipid management), and regarding educational issues in CKD and ESRD patients.

Evidence of gaps in the care of patients with renal impairment (e.g., poor hypertension control, anaemia control in CKD and dialysis patients) is published in the literature [8,9]. For the patient’s sake, these gaps must be addressed using all available methods. Enhancing the involvement of clinical pharmacists may be one potential strategy. Thus, for example, clinical pharmacist-led programmes showed higher proportions of CKD patients achieving haemoglobin target [25], increased medication knowledge [32], decreased hospitalisation rates [22], and an overall improvement in the quality of life of dialysis patients [23].
By addressing the issues illustrated in Table 4 in their general and more specified clinical work, clinical pharmacists fulfil the requirements stated in the NKF-KDOQI Guidelines “Chronic Kidney Disease: Evaluation, Classification and Stratification” [35], which explicitly highlight the need for regular medication reviews, including dosage adjustment, adverse drug event (ADE) detection, drug interaction detection, and therapeutic drug monitoring (TDM). Given the nature of their major responsibilities and tasks, clinical pharmacists interact with patients, physicians, and other health professionals and share the goal of optimising pharmacotherapy and patient care. This multidisciplinary and multilevel approach is underlined by all included studies. Clinical pharmacists, as pharmacotherapy experts, are engaged in the care of the CKD and ESRD patient population at different stages. Potential responsibilities of clinical pharmacists may comprise attainment of blood pressure, glycaemic, and lipid goals, and the early evaluation and treatment for proteinuria, anaemia, and secondary hyperparathyroidism, among others [10]. Optimal control of hyperglycaemia, including maximal suppression of urinary albumin excretion by angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in diabetic patients with persistent microalbuminuria, and hypertension can limit progression of CKD to ESRD. Evidence of improved glycaemic and blood pressure control and decreased levels of microalbuminuria through clinical pharmacists’ involvement in patient care is published [36-38]. However, due to our search strategy, studies explicitly addressing only these latter aspects are not included in this systematic review. Furthermore, no study of clinical pharmacy services in CKD patients investigating the slowing down of disease progression could be identified.

The CKD and ESRD population can be characterised by its vulnerability and susceptibility to drug-therapy-related morbidity due to many factors. Commonly reported DRPs in CKD or ESRD patients (e.g., dosing problems and medical record discrepancies) are not surprising given the complexity of dosing during either type of renal replacement therapy due to common changes in drug pharmacodynamics and pharmacokinetics [39]. This fact is further aggravated by the high number of concomitant drugs used and comorbidities, as studies report an average number of 10 to 12 drugs per day and five comorbidities for HD patients [7].

| Table 4 Comprehensive listing of clinical pharmacy activities performed in CKD and ESRD patients |
|-----------------------------------------------------------------------------------------------|
| **Medication review and monitoring of patient’s pharmacotherapy regimen**                     |
| Taking a thorough medication history, including OTC drugs, herbal supplements, drugs prescribed by non-nephrologists, and CAM drugs |
| Medication review at different time points, such as at admission, during inhospital treatment, during each dialysis session, and at discharge |
| Matching computerised medication profiles with verbally obtained medication history |
| Medication order review and checking adherence to prescribing guidelines |
| Development of discharge medication plans |
| Identification of potential or actual DRPs |
| Therapeutic recommendations (e.g. change of drugs, dose and/or interval adjustments, discontinuation of drugs, additional laboratory monitoring, nephrologist referral, addition of renoprotective drugs) |
| Therapeutic monitoring (treatment, laboratory values, and specific drugs) |
| **Education and counselling**                                                                   |
| Provision of medical and therapeutic information for patients and other health care professionals |
| Training regarding the administration of drugs (e.g. ESAs self injections) |
| Counselling on side effects, interactions |
| Compiling of guidelines for proper drug use (e. g., iron and ESAs) and implementation of treatment algorithms (e.g., hyperlipidaemia, hypertension, and renoprotective drugs) |
| Assessment and monitoring of compliance and adherence |
| **Disease management programmes**                                                               |
| Basic clinical assessments during patient visits |
| Ordering of laboratory tests |
| Co-ordering of anaemia therapies and other drugs |
| Co-prescribing within the scope of specific guidelines (e.g., anaemia management or lipid management) |
| **Further tasks**                                                                               |
| Medication use evaluation |
| Audit measures |

| Table 5 Disease versus patient-oriented outcomes |
|------------------------------------------------|
| **Disease-oriented outcomes**                   |
| Total cholesterol, LDL, HDL |
| HbA1c |
| Haematocrit, Tsat, ferritin, haemoglobin |
| SBP, DBP |
| Phosphorus, calcium-phosphorus product |
| Drug dosages (e.g., EPO dosage or ferrous dosage) |
| **Patient-oriented outcomes**                   |
| Rate of hospitalization |
| Length of stay |
| Health-related quality of life |
| Medication-related knowledge |
| Renal quality of life |
| Patient satisfaction survey |

Stemer and Lemmens-Gruber BMC Nephrology 2011, 12:35
http://www.biomedcentral.com/1471-2369/12/35

Page 9 of 12
Intensified care and additional monitoring are warranted for patients taking more than five drugs, patients with more than 12 total medication doses, patients with drug regimens prone to frequent changes and three or more concurrent disease states, and patients with a history of non-compliance, and the presence of drugs requiring TDM [40]. CKD and HD patients generally fulfil all of these criteria and therefore warrant increased monitoring. Problems with medical record discrepancies and the accuracy of medication profiles, which are among the most commonly reported DRPs, are further highlighted in a prospective observational study of 63 HD patients, which reports record discrepancies in 60% of all patients. Several clinical pharmacy studies provide insights into the risk factors for DRPs. One study [15] highlights an inverse correlation between residual kidney function (based on creatinine clearance) and the number of DRPs. Another study reports a positive correlation between the number of DRPs, on the one hand, and age and length of time on dialysis, on the other [21]. All of these aspects present opportunities for clinical pharmacist to engage in CKD and ESRD patient care.

Generally, more than three-quarters of clinical pharmacist interventions and suggestions were accepted by physicians. This physician acceptance rate is well within the range of other reported acceptance rates based on a review of clinical pharmacist impact on DRPs and clinical outcomes [6]. Due to the use of different classification systems and the resulting heterogeneity of DRPs, a profound statistical analysis was not performed.

No studies could be identified that explicitly addressed the issue of adherence in CKD or ESRD patients; nonetheless, it presents a major barrier to optimal patient care. Especially among patients taking a high number of prescription drugs, complex medication schemes and long treatment periods cause adherence to wane [41]. Guaranteeing a high level of medication knowledge may be one strategy to increase adherence and to prevent DRPs resulting from incorrect drug use or overall failure to take medications. Clinical pharmacist intervention to improve patient medication knowledge was the study objective in two of the included studies [31,32], which could be achieved.

We identified a higher proportion of studies investigating disease-oriented versus patient-oriented outcomes. Patient-oriented outcomes are those that directly matter to patients, that is, those regarding longer life and improved quality of life. From an evidence-based point of view, studies investigating patient-oriented outcomes contribute more to the overall evidence and therefore have to be weighted more heavily. However, further studies with hard endpoints, as highlighted in Table 5 as well as longer study periods are definitely warranted, as they provide further evidence on the role of pharmacists in the care of CKD and ESRD patients and other patient groups.

Several studies on clinical pharmacist involvement were identified by our search strategy, but only four of them were controlled trials (two by the same authors) with high-quality methodological design and therefore a higher evidence impact. We decided to also include abstracts in our review, because we are convinced that these small studies of the impact of clinical pharmacy on patient care contribute to the overall evidence on this topic. We could not identify any studies that specifically addressed PD patients. However, in the two studies that included PD patients, the authors did not comment on any special issues (e.g., regarding the type of DRPs or adherence). Given the complexity and specifics of drug dosing during PD, the high need for education and patient training, and the high risk of infections (e.g., peritonitis), data specific to this patient population would be interesting and warranted. We hypothesise that clinical pharmacists are routinely integrated into different aspects of PD patient care, but due to irregular clinical attachment (as compared to HD patients, who generally attend clinic three times per week), such studies are more difficult to perform.

Furthermore, regarding CKD patient studies, it was not possible to subdivide different clinical pharmacist activities and further relevant findings (e.g., common DRPs and performed interventions) according to CKD stage.

Our review is subject to publication bias. We could not identify any studies showing that clinical pharmacy interventions had a negative impact on patient care. Furthermore, studies that used DRPs and physician acceptance rates as outcome parameters lacked information about rejected interventions and the reasons for rejection. The reporting of clinical significance assessments for performed interventions increases the scientific value of clinical pharmacy research, primarily by reducing bias. Data on the impact of clinical pharmacists on hospitalised inpatients is also scarce. In addition, the majority of the studies were published in the United States. Interestingly, only one study [31] from Europe could be identified; three of the remaining four studies were from Asia [14,28,32], and one was from New Zealand [21]. However, we hypothesise that clinical pharmacists are widely engaged in the care of CKD and ESRD patients. There are, for example, special interest groups dedicated to their care, such as the United Kingdom Renal Pharmacist Group [42]. Further high-quality studies on the impact of clinical pharmacists on key issues such as adherence and disease progression are thus warranted.

Conclusions

All identified studies on the involvement of clinical pharmacists in the care of CKD and ESRD patients
showed some benefit. However, high-quality evidence on the impact of clinical pharmacy services is limited to a few studies. Clinical pharmacists address areas requiring improvement as well as unmet DRPs responsibly and preventatively. By doing so, clinical pharmacists positively contribute to the care of patients with impaired renal function and reduce the gaps in current patient care.

List of abbreviations used
ACCP: American College of Clinical Pharmacy; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; ADE: adverse drug event; BAS: before-after study; CAM: complementary and alternative medicines; CHD: coronary heart disease; CKD: chronic kidney disease; CVD: cardiovascular disease; DS: descriptive study; DRP: drug-related problem; DTP: drug-therapy problem; EKHA: European Kidney Health Alliance; ESA: erythropoiesis stimulating agent; ESRD: end-stage renal disease; HD: haemodialysis; IPA: International Pharmaceutical Abstracts database; RCT: randomised controlled trial; RRT: renal replacement therapy; PD: peritoneal dialysis; TDM: therapeutic drug monitoring.

Acknowledgements
We would like to thank the multidisciplinary health care team of the internal nephrology ward and the staff of the pharmacy department for continual support during the review and preparation of the manuscript.

Author details
1Department of Pharmacology and Toxicology, University of Vienna, Althanstraße 14, 1090 Vienna, Austria. 2Pharmacy Department, Vienna General Hospital, Währinger Gürtel 18-20, 1090 Vienna, Austria.

Authors’ contributions
GS was responsible for the study design, data collection and interpretation and preparation of the manuscript. RLG was responsible for the study design, data interpretation and review of the manuscript. All authors read and approved the final manuscript.

Competing interests
The study was performed within a clinical pharmacy project that was funded by Amgen. The authors declare that there are no financial or other conflicts of interests with respect to the contents of the article.

Received: 10 January 2011 Accepted: 22 July 2011 Published: 22 July 2011

References
1. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP: Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001, 37(6):1177-1183.
2. European Kidney Health Alliance: Chronic kidney disease and diabetes - A major threat to Europe’s health[http://www.ekha.eu/ukr_eng/newsroom/2010/03_03_10.pdf].
3. Go AS, Chertow GM, Fan D, D’Agostino R, Massaro JM, Kannel WB: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
4. Danovitch GM: Handbook of Kidney Transplantation. Philadelphia: Lippincott Williams & Wilkins; 4 2000.
5. Kaboli PJ, Roth AB, McClumpha B, Schnipper JL: Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006, 166(9):955-964.
6. Viktik KL, Blix HS: The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol 2008, 102(3):275-280.
7. Manley HJ, Cannella CA, Bailey GR, St Peter WL: Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005, 46(4):669-680.
8. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP: Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 2001, 12(8):1713-1720.
9. Owen WF Jr: Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 2003, 14(7 Suppl 2):76-80.
10. Zillich AJ, Saseen JJ, Dehart RM, Dumo P, Grabe DW, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki MC, Joy MS: Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy 2005, 25(1):123-143.
11. Stemer G, Lemmens-Gruber R: Clinical pharmacy services and solid organ transplantation: a literature review. Pharm World Sci 2010, 32(1):7-18.
12. Possidente CJ, Baile GR, Hood VL: Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health Syst Pharm 1999, 56(19):1961-1964.
13. Castro R, Leung J, Song J, Patel R, Jobalia A: Outcomes of implementing a medication therapy management service for dialysis patients [abstract]. ASHP Midyear Clinical Meeting 2009, p506.
14. Lim SB, Lim GK, Khoo AL, Sivaraman P: Evaluation of the clinical and economic impact through a focused drug therapy review program in in-flight patients with renal impairment [abstract]. ASHP Midyear Clinical Meeting 2003, 38(Dec):P-273(E).
15. Patel HR, Pruchnicki MC, Hall LE: Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005, 39(1):22-27.
16. Lee J, Lee A, Chiao P, Chee N, Johansen K: Impact of a pharmacist’s collaborative management, adherence, and medication education program (CAMP) in an ambulatory renal clinic. ASHP Midyear Clinical Meeting 2009.
17. Tang I, Vlahnos D, Hatoun H, Lau A: Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther 1993, 15(2):459-464.
18. Kaplan B, Shimp LA, Mason NA, Ancione FJ: Chronic hemodialysis patients. Part II: Reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother 1994, 28(3):320-324.
19. Grabe DW, Low CL, Baile GR, Eisel G: Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997, 47(1):117-121.
20. Erickson AL, Saumita PM, Cotugno MC: Implementation of a pharmacist medication review clinic for chronic hemodialysis patients. Ann Intern Med 1995, 28(3):320-324.
21. Mirkov S: Implementation of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health Syst Pharm 2008, 65(21):2011-2013.
22. Mirkov S: Implementation of a pharmacist medication review clinic for hemodialysis patients. N Z Med J 2009, 122(1297):25-37.
23. Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Marley H: Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care a 2-year, randomized, controlled study. Pharmacotherapy 2009, 29(12):1433-1440.
24. Pai AB, Boyd A, Chavez A, Marley HJ: Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study. Hemodial Int 2009, 13(1):72-79.
25. Bucaloiu JD, Aker S, Bermudez MC, Mainali R, Brown BL, Roberts SS, Hartle E: Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface 2007, 20(6):26-30.
26. Joy MS, Candiani C, Vaillancourt BA, Chiao P, Hogan SL, Falk RJ: Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy 2007, 27(5):734-744.
27. To LL, Stoner CP, Stolley SN, Buenavieja JD, Ziegler TW: Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health Syst Pharm 2001, 58(1):2061-2065.
28. Viola RA, Abbott KC, Welch PG, McMillan RJ, Sheikh AM, Yuan CM: A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrol 2002, 3:9.
29. Kimura T, Arai M, Masuda H, Kawabata A: Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. Biol Pharm Bull 2004, 27(11):1851-1853.
29. Manley HJ, Drayer DK: Clinical pharmacy interventions reduce ambulatory hemodialysis (HD) patients cardiovascular risk [abstract]. J Am Soc Nephrol 2004, 15:F-FC012.

30. Walton T, Holloway KP, Knauss MD: Pharmacist-managed anemia program in an outpatient hemodialysis population. Hospital Pharmacy 2005, 40(12):1051-1056.

31. Allenet B, Chen C, Romanet T, Vialtel P, Calop J: Assessing a pharmacist-run anemia educational programme for patients with chronic renal insufficiency. Pharm World Sci 2007, 29(1):7-11.

32. Sathvik BS, Mangasuli S, Narahari MG, Gurudev KC, Parthasarathi G: Medication knowledge of hemodialysis patients and influence of clinical pharmacist provided education on their knowledge. Indian J Pharm Sci 2007, 69(2):232-239.

33. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD: Drug-related problems: their structure and function. DICP 1990, 24(11):1095-1097.

34. Hatoum HT, Hutchinson RA, Witte KW, Newby GP: Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 1988, 22(3):252-259.

35. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):1-266.

36. Cioffi ST, Caron MF, Kalus JS, Hill P, Buckley TE: Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother 2004, 38(5):771-775.

37. Kiel PJ, McCord AD: Pharmacist impact on clinical outcomes in a diabetes management program via collaborative practice. Ann Pharmacother 2005, 39(11):1828-1832.

38. Borenstein JE, Gruber G, Saltiel E, Wallace J, Ryu S, Archi J, Deutsch S, Weingarten SR: Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003, 23(2):209-216.

39. Verbeeck RK, Musuamba FT: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009, 65(8):757-773.

40. Koehler J, Abramowitz PW, Swine SE, Daniels CE: Indicators for the selection of ambulatory patients who warrant pharmacist monitoring. Am J Hosp Pharm 1989, 46(6):729-732.

41. Loghman-Adham M: Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003, 9(2):155-171.

42. UK Renal Pharmacy Group. [http://www.renalpharmacy.org.uk].

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2369/12/35/prepub

doi:10.1186/1471-2369-12-35
Cite this article as: Stemer and Lemmens-Gruber: Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrology 2011 12:35.